Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/8269

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/8269

Title:	Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice
Authors:	Yiang, GT (Yiang, Giou-Teng);Harn, HJ (Harn, Horng-Jyh);Yu, YL (Yu, Yung-Luen);Hu, SC (Hu, Sheng-Chuan);Hung, YT (Hung, Yu-Ting);Hsieh, CJ (Hsieh, Chia-Jung);Lin, SZ (Lin, Shinn-Zong);Wei, CW (Wei, Chyou-Wei)
Contributors:	Department of Biotechnology
Keywords:	RECOMBINANT ADENOASSOCIATED VIRUS;DIRECTED GENE-THERAPY;CANCER A549 CELLS;IN-VIVO;EFFICIENT TRANSDUCTION;TRANSGENE EXPRESSION;IMMUNOGENE THERAPY;IMMUNE-RESPONSE;DENDRITIC CELLS;PROTEIN-KINASE
Date:	2009-05
Issue Date:	2010-03-26 02:29:28 (UTC+0)
Publisher:	Asia University
Abstract:	Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.
Relation:	JOURNAL OF BIOMEDICAL SCIENCE 16: Art. No. 47
Appears in Collections:	[生物科技學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	428	View/Open
164.doc		36Kb	Microsoft Word	288	View/Open

Loading...